BPC-157 vs TB-500

01 · At a glance

Two reviewed records, side by side

Readers usually arrive here asking which of the two heals injuries faster, or whether to use them together. The reviewed records answer neither question, because neither molecule has reliable human outcome evidence for healing. What the records can do is show what each is, what has actually been studied, and what the governing bodies have said.

Bottom line. Neither BPC-157 nor TB-500 has established human healing outcomes in the reviewed records. BPC-157 has a substantial preclinical literature plus early human work and registered research; TB-500 has an unresolved identity question and no adequate human outcome evidence. Both are prohibited in tested sport.

02 · Evidence profile

Four questions, graded separately

The profile is never averaged into a single score. A molecule can be well characterized on one axis and unresolved on another, and the pattern carries the information.

03 · Research footprint

What kind of records sit behind each brief

Counting record types is a blunt instrument, but it makes the development stage visible. A brief built on drug labels and randomized trials is not in the same position as one built on preclinical work, registry entries, or an advisory-stage agency review.

04 · Claim-by-claim

Every reviewed claim, with its verdict and scope

Verdicts apply to the exact wording shown. Each links to a versioned claim record with its own sources and review provenance.

05 · Product boundary

The molecule is not the finished product

Evidence attaches to a studied product: a specific sequence, formulation, route, and supply chain. A shared ingredient name does not transfer that evidence to another vial.

07 · Framing

Why these two get compared at all

BPC-157 and TB-500 are grouped in the same family in the reviewed briefs—recovery and repair claims—and each brief lists the other among its related records. The pairing is a market phenomenon rather than a scientific one: both circulate with the same promise of faster tendon, muscle, and soft-tissue repair, and both are sold through the same channels with the same “research use only” framing.

Once you look at the records, the symmetry breaks down quickly. BPC-157 is graded Emerging, with an evidence context of investigational human outcomes. TB-500 is graded Insufficient, with an evidence context of preclinical or formulation evidence. Those are different classifications describing different situations, and the difference is not a matter of degree.

The useful comparison is therefore not which one works better. It is what kind of gap each one has, because the gaps are different, and knowing which gap you are looking at changes what would count as evidence closing it.

08 · Evidence footprint

Preclinical signal, human silence

The BPC-157 brief is unusually explicit about the shape of its evidence base. The preclinical literature contains positive signals in cell and animal models, including tendon-healing models, and the brief cites a rat and cell tendon-outgrowth study directly. The corresponding claim—that BPC-157 improves tendon healing in preclinical models—is graded Supported with scope, and the scope is stated: cell and animal tendon models only, not clinical healing outcomes in people.

The neighbouring claim, that BPC-157 heals tendons and muscles in people, is graded Not established. The brief records that small human pilot work and registered clinical research now exist, and cites a safety pilot of intravenous infusion in humans, a translational-barriers review, and an active hamstring-strain trial registration. It then states the rule that makes this page necessary: early, uncontrolled, or registered research is not the same as a replicated patient benefit, and a trial listing is not a positive result.

TB-500's record has a different shape. FDA's 2026 briefing on TB-500-related bulk substances evaluated identity, characterization, and a proposed wound-healing use, and the brief reports that FDA found no adequate human clinical outcome evidence for compounded TB-500 wound-healing use. That is why the human-outcomes axis is graded Unclear rather than Limited: the brief is not reporting a small body of human evidence that falls short, it is reporting an evidence review that did not find an adequate body at all.

The practical consequence is that the two molecules would need different things to move. BPC-157 has a plausibility case built in animals and a growing human research footprint; what it lacks is controlled human outcome data. TB-500 lacks that too, but it also lacks a settled answer to a prior question.

09 · Identity

TB-500 has an identity problem before it has an evidence problem

The single most load-bearing fact in the TB-500 brief is not about healing at all. FDA describes TB-500 as a seven-amino-acid fragment—the N-terminal acetylated 17-23 fragment—of the much larger thymosin beta-4 molecule. The claim that TB-500 is the same thing as thymosin beta-4 is graded Misleading on exactly that basis.

This matters because most of the enthusiasm around TB-500 borrows credibility from research on full-length thymosin beta-4. The brief states the boundary: evidence about the full protein cannot automatically be transferred to the fragment. If a marketing page cites thymosin beta-4 literature to support a TB-500 product, it has performed a substitution that the identity record does not permit.

The product-certainty axis reflects the downstream consequences. The TB-500 brief scores it Unclear and lists the reasons: nomenclature, salt form, purity, sterility, and fragment-versus-protein distinctions all create major uncertainty. Internet naming and certificates do not establish product identity or clinical equivalence.

BPC-157's product-certainty axis is also graded Unclear, but for a narrower reason: there is no validated approved formulation, and identity and purity vary outside formal research. Its brief frames the same lesson as a chain of separate objects—a peptide sequence, a nominated bulk substance, a clinical-study product, and a consumer vial are separate evidence objects, and identity and product quality cannot be assumed from the name. For BPC-157 the sequence is not in dispute; what is in dispute is what is in the vial. For TB-500, both questions are open.

10 · Status

What the regulators and anti-doping records say

Neither molecule has an approved product. The BPC-157 brief records its status as investigational with no approved formulation; the TB-500 brief records that there is no FDA-approved TB-500 drug product. Neither has an FDA-approved indication.

Both appear in FDA compounding-review material, and both briefs are careful about what that means. The BPC-157 brief notes that FDA's July 2026 advisory-committee briefing evaluated BPC-157-related bulk substances for a nominated ulcerative-colitis use and documented evidence and safety gaps, then states the limit directly: that advisory-stage record supports scrutiny, but it is not a final FDA determination. Being reviewed is not the same as being rejected, and neither is the same as being approved.

On anti-doping the records converge. Both briefs carry a normalized status of Prohibited. BPC-157 is listed under WADA's S0 non-approved substances category and is prohibited at all times for covered athletes. TB-500 is named on the 2026 WADA Prohibited List as a prohibited thymosin-beta-4 derivative. The claim that athletes can use BPC-157 because it is not a steroid is graded Misleading, and the claim that TB-500 is allowed in tested sport is graded Misleading. The reasoning is the same in both cases and is worth stating plainly: the prohibited list is not a list of steroids, and a substance's absence from any approval pathway is precisely what places it in category S0.

The site records this as a status, not as personal clearance. Athletes remain responsible for checking the current list, Global DRO, and their own governing body's rules.

11 · Boundary

The question this page will not answer

The highest-volume version of this comparison is not really a comparison. It is a request for a protocol: which one, how much, together or separately, for how long. Both briefs close that door explicitly, and this page keeps it closed.

The BPC-157 brief states that the site will not provide self-injection, reconstitution, dosing, sourcing, or stack instructions, and adds that “research use only” does not establish quality or make a product appropriate for human use. The TB-500 brief uses the same boundary: no sourcing, reconstitution, injection, cycle, stack, or injury-treatment instructions.

There is also a substantive reason beyond policy. A combination claim requires evidence about the combination, and neither brief records any. Two molecules without established individual human outcome evidence do not produce a supported combined claim by being mentioned in the same sentence.

12 · Limits

What the reviewed records do not say

A comparison is only as good as its silences. These are the questions readers bring to this pairing that the reviewed records cannot answer, listed so that no one mistakes an absence for an omission.

• The reviewed records contain no head-to-head comparison of BPC-157 and TB-500, and no study of the two used together.
• Neither brief records a characterized human pharmacokinetic profile adequate for comparison; BPC-157's is described as sparse and TB-500's is described in terms of fragment identity rather than clinical behaviour.
• No human outcome evidence for tendon, muscle, or wound healing is recorded for either molecule, so no healing-speed comparison is possible.
• The data layer records no comparative human safety dataset for either molecule; BPC-157's is described as too small for confident risk estimates and TB-500's as inadequate.
• FDA's compounding-review records for both substances are advisory-stage, and the repository holds no final agency determination for either.

Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist, and it is not a dosing, sourcing, or treatment guide.